Rivaroxaban for Venous Thromboembolism Prophylaxis in Abdominoplasty: A Multicenter Experience by Flugstad, Nicholas A. et al.
Rivaroxaban for Venous Thromboembolism
Prophylaxis in Abdominoplasty: A Multicenter
Experience
Joseph P. Hunstad, MD, FACS; Daniel J. Krochmal, MD;
Nicholas A. Flugstad, MD; Bill G. Kortesis, MD;
Adam C. Augenstein, MD; and Gary R. Culbertson, MD, FACS
Abstract
Background: Abdominoplasty, a commonly performed aesthetic procedure, is considered to have an increased risk of venous thromboembolism (VTE)
events. At present, routine VTE chemoprophylaxis following abdominoplasty remains controversial.
Objectives: This study evaluates the authors’ experience with rivaroxaban, an oral Factor Xa inhibitor, for VTE prophylaxis in abdominoplasty patients.
Methods: A retrospective case series was conducted. All patients who underwent abdominoplasty and received rivaroxaban were included. The prophy-
lactic dose was 10 mg daily for 7 days, beginning 12 hours postoperatively. Patient demographics, comorbidities, and type of surgery were recorded. The
primary outcome measured was hematologic complication, including VTE, hematoma requiring operative evacuation, and need for blood transfusion.
Results: From September 2012 until July 2014, 132 patients (122 women and 10 men) underwent abdominoplasty surgery and received rivaroxaban
postoperatively. Mean patient age was 43.7 years, and mean body mass index was 27.1. One hundred twenty-five patients also underwent abdominal
muscle plication. Eleven patients underwent a fleur de lis vertical skin resection component. One hundred patients underwent concomitant abdominal lipo-
suction, while 79 patients also had back liposuction. Only 1 patient had a symptomatic VTE event. Three patients had a hematoma requiring operative evac-
uation, and all went on to heal without sequelae. Two patients received a blood transfusion for anemia during their course of rivaroxaban.
Conclusions: Oral rivaroxaban administration for chemoprophylaxis in abdominoplasty patients is safe, with low rates of symptomatic VTE and hemato-
ma formation. The authors continue routine use of the medication for patients at increased risk for VTE events.
Level of Evidence: 4
RiskAccepted for publication June 2, 2015; online publish-ahead-of-print July 9, 2015.
Abdominoplasty, one of the most popular aesthetic proce-
dures, was performed 160,077 times in 2013, according to
statistics released by the American Society for Aesthetic
Plastic Surgery.1 A serious and potentially fatal complication
of abdominoplasty is venous thromboembolism (VTE). A
systematic review by Hatef et al demonstrated the rate of
VTE was 0.34% for abdominoplasty-only patients, 0.67%
for patients undergoing abdominoplasty with a concomitant
plastic surgical procedure, and 3.4% for patients undergoing
circumferential abdominoplasty.2 Tracking Operations and
Outcomes for Plastic Surgeons (TOPS) and CosmetAssure
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data over 4 years demonstrated deep vein thrombosis (DVT)
and pulmonary embolism (PE) rates of 0.3% and 0.1%, re-
spectively, for abdominoplasty as a single procedure.3
Murphy et al reported 1 DVT and 2 PEs on 243 abdomino-
plasty and panniculectomy patients despite 100% compli-
ance with Surgical Care Improvement Project (SCIP) VTE
recommendations.4 In a single institutional series, VTE was
5.0% in abdominoplasty patients and 7.7% in circumferen-
tial abdominoplasty patients.5
Despite the relative frequency of this serious complication,
the accepted standard methods to prevent VTE in abdomino-
plasty patients, including chemoprophylaxis, remain a hot
topic for debate.6-11 Reasons for not incorporating chemopro-
phylaxis may be the low rate of VTE when patients are prop-
erly selected, anesthetic is limited in depth and duration,
patients are properly positioned, mechanical prophylaxis is
employed, and patients ambulate in the early postoperative
period.12-15 Additionally, because VTE chemoprophylactic
agents block portions of the coagulation cascade to inhibit
blood clot formation, the risk of bleeding complications is
theoretically increased.
Rivaroxaban (Xarelto) is an oral Factor Xa inhibitor.
The medication gained United States Food and Drug
Administration (FDA) approval in 2011 for DVT prevention
for patients undergoing hip or knee replacement surgery.16
At the typical prophylactic dosage (10 mg administered
once daily), measuring drug levels is not necessary, and no
adjustments are needed for weight or creatinine clearance.
We present the retrospective experience of 2 surgical cen-
ters that use rivaroxaban for routine VTE prophylaxis for
patients undergoing abdominoplasty.
METHODS
A retrospective chart review was conducted on all patients
who received postoperative rivaroxaban (Xarelto) after
having undergone a procedure for removal of excess abdom-
inal skin at 1 of the 2 clinical sites. Most patients also under-
went additional interventions to contour the torso including
muscle plication, fleur de lis vertical skin resection, liposuc-
tion, and excision of excess back skin (circumferential
abdominoplasty or bra line back lift). All procedures were
performed under general anesthetic at the American
Association for Accreditation of Ambulatory Surgery
Facilities- or Joint Commission-accredited ambulatory surgi-
cal facilities associated with the practices. Both centers initi-
ated rivaroxaban independently of each other following
informal discussion with community hematologists, as ease
of administration and patient compliance were felt likely to
be improved with rivaroxaban over injectable prophylactic
measures. A dose of 10 mg, initiated 12 hours postoperative-
ly, was recommended. Since this medication was adminis-
tered in abdominoplasty patients, the usage was technically
off-label as rivaroxaban has been FDA approved for VTE
prophylaxis in hip and knee replacement patients. Because
the medication was approved for a related (but not identical)
indication, a specific formal written consent regarding its
use following abdominoplasty was not obtained. The
routine consultation and surgical consent process incorporat-
ed the discussion regarding the risks and benefits of rivaroxa-
ban use, as well as notification of its off-label administration.
The study conformed to the World Medical Association
Declaration of Helsinki.17 As this was a retrospective chart
review of previously established postoperative protocols,
formal Institutional Review Board approval for this study was
not sought.
All clinical and operative notes and laboratory and radio-
graphic data were utilized for data collection. Data on demo-
graphics, comorbidities, body mass index (BMI), Factor V
Leiden mutation, operation performed, length of anesthetic,
and postoperative complications were recorded. Patients
were included in the analysis if there was a follow-up of at
least 30 days, or if follow-up was less than 30 days but a com-
plication was noted. A subset of our patients were deemed
high risk for VTE based on personal or family history of
blood clots and were referred to a hematologist preoperative-
ly; these patients were included in our review if they received
rivaroxaban 10 mg daily for prophylaxis as recommended by
the hematologist.
At 1 center, formal risk stratification using the 2004
Davison-Caprini Scale18 was employed; prophylactic rivar-
oxaban 10 mg was prescribed for 14 days if indicated (high
risk, 3 factors or more). The decision to use this scale was
made because of its relative ease of interpretation and com-
pletion compared with other scales. At the other center,
rivaroxaban was administered routinely for all abdomino-
plasty patients, as they were deemed high risk based on the
procedure type as cited in the ASPS VTE task force recom-
mendations (which utilized the 2005 Caprini scale),19 and
was prescribed for 7 days. As a standard practice at both
centers, the first dose was given 12 hours post-procedure if
there was no concern for postoperative bleeding. Additional
prophylaxis including perioperative sequential compression
devices, knee flexion when supine, early ambulation, and
maintaining adequate hydration, was standard practice.
Follow-up was the time from surgery until the most
recent visit to the practice. A patient was considered a
current smoker if they endorsed smoking at the preopera-
tive visit (typically within 4 weeks of surgery) and was not
considered a smoker if they reported a negative smoking
history or had a negative urine cotinine test preoperatively.
A patient was considered positive for contraceptive medica-
tion or hormone replacement therapy if they endorsed
taking those medications in any form (pill, cream, ring, in-
trauterine, injection) at the preoperative visit; patients on
these medications were encouraged to discontinue usage 2
weeks prior to surgery (with the exception of low-dose in-
trauterine devices).
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RESULTS
The operative database was queried on July 11 2014. The
chart review included all patients undergoing abdominal
skin excision surgery during the time period from September
20, 2012 (the first patient to receive the medication) until the
date of the query. One hundred eighty-seven patients had
some form of abdominal skin resection during the study.
Twenty-six patients were part of a trial involving tissue glue
being evaluated for FDA approval and, therefore, did not
receive chemoprophylaxis. Four patients had simple scar re-
visions, while 3 patients had limited surgeries where chemo-
prophylaxis was not felt to be indicated based on surgeon
judgment. Three patients had surgeries at a local hospital
not affiliated with the surgery centers and were excluded.
Fifteen patients received enoxaparin (5 because of a hema-
tologist’s recommendations for a hypercoagulable state, 10
because the prescriptions were given to the patient preopera-
tively prior to the switch to rivaroxaban). Two patients un-
derwent operative hematoma evacuation prior to receiving
rivaroxaban and were excluded. One hundred thirty-four pa-
tients, therefore, underwent abdominoplasty and received at
least 1 dose of rivaroxaban. Two patients had follow-up of
less than 30 days without a complication and were, there-
fore, excluded. The remaining 132 patients who received
rivaroxaban and had adequate follow-up were included in
the analysis.
Demographic, body mass index (BMI), and comorbidity
data are summarized in Table 1. For the 132 patients, there
were 122 females (92%) and 10 males (8%). Mean patient
age was 43.7 years (range, 19.8-71.5 years). Mean BMI was
27.1 (range, 17.3-45.9), and 33 patients (25%) had a
BMI>30. Ten patients were current smokers, 2 patients had
diabetes, and 15 patients reported hypertension. Thirty-four
patients were on oral contraceptives or hormone replacement
therapy at the preoperative visit. Ten patients reported a
family history of blood clots, and 3 patients had a personal
history of DVT. Of the 112 patients for which we obtained
preoperative Factor V Leiden data, 2 were heterozygous for
the mutation. There were no patients who were homozygous
for the Factor V Leiden mutation included in the analysis.
Mean follow-up was 7 months (range, 1-20 months).
Operative details may be found in Table 2. As mentioned,
all 132 patients had excision of excess abdominal skin. One
hundred twenty-five patients (95%) also had a muscle plica-
tion. Eleven patients (8%) had a fleur de lis vertical skin
resection. One hundred patients (76%) had abdominal lipo-
suction. Twenty-two patients (17%) also had excision of
back skin (either circumferential abdominoplasty/lower
body lift or a bra line backlift). Seventy-nine patients (60%)
had liposuction of their back. Ninety-three patients (70%)
underwent additional procedures. Table 3 lists the proce-
dures performed on individual patients, amount resected,
and operative time. Additional procedures (eg, extremity
contouring, fat grafting, breast or facial procedures) are also
included. Mean resection weight was 10.6 lbs (range,
0.1-34.8 lbs), and 37 patients (28%) had more than 15
pounds removed. Mean length of anesthetic was 353.8
minutes (range, 137-640 minutes).
Complication data may be found in Table 4. Of our 132
patients who received postoperative rivaroxaban, 1 patient
(0.76%) had a DVT/PE. The patient was a 61 year old
woman, BMI 27.4, Factor V Leiden negative, who under-
went abdominoplasty with muscle plication and circumfer-
ential trunk liposuction. On the fourth visit, on
postoperative day (POD) 18, she reported a 2-day history of
calf pain affecting her ambulation and shortness of breath
Table 2. Operative Data By Procedure
Procedure No. (%)
Abdominal skin resection 132 (100)
Muscle plication 125 (94.7)
Abdominal liposuction 100 (75.8)
Back liposuction 79 (59.8)
Fleur de lis vertical skin resection 11 (8.3)
Back skin resection (lower body or bra line
backlift)
22 (16.7)
Additional procedures 93 (70.5)
Table 1. Demographic Data
Number (%) ± SD Range
Total cases 132 NA
Mean age (years) 43.7 ± 10.2 19.8-71.5
Gender
Women 122 (92.4%) NA
Men 10 (7.6%) NA
BMI 27.1 ± 5.5 17.3-45.9
Diabetic patients 2 (1.5%) NA
Current smokers 10 (7.6%) NA
HTN 15 (11.4%) NA
Contraceptives/HRT 34 (25.8%) NA
Family h/o VTE 10 (7.6%) NA




BMI, body mass index; HRT, hormone replacement therapy; h/o, history of; HTN, hypertension;
NA, not applicable; VTE, venous thromboembolism.
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with normal conversation and sat for an extended time
during a trade show shortly before the symptoms began.
Ultrasound confirmed a left popliteal vein DVT, and a CT
scan confirmed a PE, moderate-large clot burden affecting
all lobes. She then began a therapeutic dose of enoxaparin
and was transitioned to a therapeutic dose of Xarelto (20
mg daily) for DVT/PE treatment. While she indicated a
family history of blood clots preoperatively, further inquiry
postoperatively determined an extensive family history
with multiple family members affected that had not been
disclosed prior to surgery. She recovered uneventfully.
Three patients (2.3%) had a hematoma requiring opera-
tive evacuation. One patient (35 year old woman, BMI 19,
using oral contraceptives, underwent a non-liposuction
abdominoplasty with muscle plication and subfascial breast
augmentation) had a hematoma at the abdominoplasty site
evacuated on POD 2. One patient (28 year old woman, BMI
26.6, using oral contraceptives, underwent abdominoplasty
with muscle plication and abdominal liposuction) had a he-
matoma at the abdominoplasty site evacuated on POD
3. One patient (37 year old woman, BMI 20.8, underwent
abdominoplasty with muscle plication with abdominal lipo-
suction, and a mastopexy) had a hematoma of the left breast
site evacuated on POD 2.
Three patients (2.3%) received blood transfusions
following their procedures after taking at least 1 dose of
rivaroxaban. One patient underwent abdominoplasty with
muscle plication and circumferential trunk liposuction
Table 3. Operative Data by Patient
Procedure Number n = (%) Add Proc n= Weight removed mean lbs ± SD Case length mean min ± SD
MP 13 (9.8%) 7 1.81 ± 2.54 207 ± 65.4
MP, ALipo 19 (14.4%) 8 8.45 ± 7.6 340.1 ± 130.6
MP, ALipo, FDL 1 (7.6%) 1 14.3 312
MP, ALipo, FDL, BSkin 2 (1.5%) 2 22.8 ± 4.5 489.5 ± 13.4
MP, ALipo, FDL, BSkin, BLipo 1 (0.76%) 1 11.9 483
MP, ALipo, BSkin 4 (3.3%) 4 12.6 ± 15.2 396.5 ± 44.9
MP, ALipo, BLipo 68 (51.5%) 50 12.6 ± 5.8 375 ± 70.9
MP, FDL 1 (0.76%) 0 27.9 263
MP, FDL, BSkin 5 (3.8%) 3 19.0 ± 7.3 448.6 ± 92.2
MP, FDL, BSkin, BLipo 1 (0.76%) 1 19.6 390
MP, BSkin 6 (4.5%) 6 4.7 ± 3.0 344.7 ± 79.2
MP, BSkin, BLipo 1 (0.76%) 1 9.7 407
MP, BLipo 3 (2.3%) 3 3.8 ± 2.7 363.3 ± 47.5
ALipo 1 (0.76%) 0 1.8 307
ALipo, BLipo 4 (3.0%) 4 8.1 ± 2.4 349.2 ± 37.9
ALipo, BSkin 1 (0.76%) 0 2.8 250
BLipo, BSkin 1 (0.76%) 1 4.6 258
All patients had abdominal skin resected. Add Proc, had additional procedures performed; ALipo, abdominal liposuction; BLipo, back liposuction; BSkin, excision of excess back skin, either a lower
bodylift/circumferential abdominoplasty or a bra line backlift; FDL, fleur de lis vertical skin resection; MP, muscle plication.
Table 4. Complications
No (%)
VTE event 1 (0.76)
Hematoma with operative evacuation 3 (2.3)
Blood transfusion POD 0-14 2 (1.5)
Blood transfusion POD ≥15 1 (0.76)
Wounds with dressing changes 33 (25.0)
Seroma with needle aspiration 38 (28.8)
Infections (including cellulitis) 27 (20.5)
POD, postoperative day; VTE, venous thromboembolism.
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along with fat grafting to her buttocks and face. On POD 3
she developed symptomatic anemia with a Hgb of 8.5 g/dL,
received a blood transfusion, and was discharged the fol-
lowing day. One patient had a circumferential abdomino-
plasty with rectus plication and liposuction to her inner
thighs. On POD 1, she developed symptomatic anemia with
a Hgb of 6.9 g/dL; she was discharged on POD 3 following
blood transfusion. Both of these patients resumed their
prophylactic dose of rivaroxaban once their hemoglobin sta-
bilized without further issues with bleeding or anemia.
Another patient, a 56 year old man, underwent a fleur de lis
abdominoplasty with muscle plication. In the initial postop-
erative period, he did well but developed a wound in the ver-
tical limb of his abdominoplasty that underwent serial
debridement in clinic. Three weeks postoperatively (2 weeks
after the rivaroxaban course) the wound began bleeding at
home; he presented to a local emergency department where
he received a blood transfusion for anemia. His wound sub-
sequently healed with serial dressing changes.
Additional complications included seroma formation
with needle aspiration (n= 38, 28.8%), wounds with dres-
sing changes at any operative site (n= 33, 25%), and infec-
tions (n= 27, 20.5%). We attribute the relatively high
seroma rate to frequent use of concomitant liposuction with
a large volume of tumescent and aggressively aspirating
even very small fluid collections. We attribute our relatively
high infection rate to our low threshold for starting antibiot-
ics for patients with a possible early cellulitis.
DISCUSSION
Regarding the decision to employ VTE chemoprophylaxis,
Trussler and Tabbal stated, “The precarious balance of the
coagulation cascade is the pivot point for two of the most
common surgical complications: bleeding and thrombo-
sis.”20 Hematomas requiring operative evacuation, and
DVTs requiring prolonged anticoagulation to minimize
propagation or post-thrombotic syndrome, are not pleasant
events. A fatal PE is a nightmare scenario, as is massive
postoperative hemorrhage leading to incapacitation or
death. Postoperative complications, while difficult to toler-
ate for all patients, are perhaps more difficult to come to
terms with for the healthy patient undergoing an entirely
elective procedure. Continued study of methods to reduce
complications while not causing a compensatory increase
in others (eg, bleeding vs clotting) is imperative.
Ideally, chemoprophylaxis should: (1) be effective at pre-
venting VTE, (2) have a low risk of adverse events such as
hematoma formation, (3) be inexpensive, (4) be without the
need for monitoring levels or adjusting doses based on
weight or creatinine, (5) be easily administered and tolerated
by the patient, and (6) be administered as part of a regular
patient protocol without consulting a risk-stratification scale.
At this time, no agent is ideal, and one must continue to
weigh the risks and benefits of chemoprophylactic adminis-
tration for any patient. Clinicians should consult a recom-
mendation or risk-assessment scale that they find useful to
help guide this decision.
Rivaroxaban has demonstrated effectiveness for VTE pro-
phylaxis for patients undergoing hip and knee replacement
(initial FDA indications), and bleeding rates were found to
be similar to enoxaparin.21,22 Regarding cost compared with
enoxaparin, rivaroxaban demonstrated a cost savings in pa-
tients with total hip and total knee replacements.23 Our pa-
tients report paying approximately $90 for a 1 week course if
insurance does not cover the medication. If the typical pro-
phylactic dosing is utilized, measuring drug levels is not nec-
essary, and no adjustments are needed for dosage based on
weight or creatinine clearance. Regarding compliance, no
patients in our series reported difficulty tolerating the medi-
cation or were burdened by its administration.
There are myriad risk assessment modules and institution-
al guidelines to assist the surgeon with the choice of
employing chemoprophylaxis,18,19,24-30 sometimes with con-
flicting recommendations. In our series, the average abdomi-
noplasty patient (age 43.7 yrs, BMI 27.1, operative time 353
minutes), has a 2004 Davison-Caprini Score of 3, 2005 Caprini
Score of 4, 2010 Caprini Score of 6, and a Patient Safety
Committee Score of “high”. One center utilized the 2004
Davison-Caprini scale to guide rivaroxaban administration,18
and another routinely administered rivaroxaban based on the
heightened VTE risk for abdominoplasty patients, as cited in
the American Society of Plastic Surgeons VTE task force rec-
ommendations (which utilized the 2005 Caprini scale).19 As
there is no VTE risk-assessment scale that has been formally
validated in the outpatient abdominoplasty patient popula-
tion, the choice of a particular scale is currently at the discre-
tion of the surgeon. This is not the first published study on
rivaroxaban in abdominoplasty patients. Dini and colleagues
evaluated rivaroxaban for postoperative VTE prophylaxis in
abdominoplasty patients.31 In a prospective, randomized,
double-blinded, placebo controlled study, 40 patients consid-
ered high risk were randomized to receive either rivaroxaban
10 mg or placebo daily for 10 days. The drug was first admin-
istered 8 hours after surgery. After 27 surgeries, the study was
stopped due to a high complication rate; it was noted that all 8
hematomas up to that point had occurred in the study (rivar-
oxaban) group. While the increased bleeding rate may have
resulted from the timing of the first dose being only 8 hours
after surgery, we believe that it was likely the routine postop-
erative use of tenoxicam (a nonsteroidal anti-inflammatory
drug [NSAID]) that potentiated bleeding when used in combi-
nation with rivaroxaban. When patients are instructed to
avoid NSAIDs while on rivaroxaban, and when giving our
first dose 12 hours after surgery, we have not experienced un-
acceptably high rates of bleeding complications.
While we are unhappy with any VTE event, our 1
patient with a DVT/PE (0.76%) in this study is consistent
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with the incidence in the literature. This patient also had an
extensive family history of blood clots, and it would have been
the practice at the institution where shewas treated to have her
referred to a hematologist preoperatively, and perhaps keep
her on DVT chemoprophylaxis for a longer period of time (she
developed symptoms of a DVT 9 days after she would have
stopped her rivaroxaban). Regarding hematoma, Stewart et al
published their experience with 278 abdominoplasties and re-
ported a 3% hematoma rate (and 1 patient had a pulmonary
embolus).32 Specific VTE prophylactic measures were not
mentioned in this series; however, upon communication with
Mr. Stewart, he relayed that heparin administration was not a
standard practice at that time. Out of our 132 patients, the he-
matoma formation requiring operative evacuation in 3 patients
(2.3%) is also acceptable, with 2 hematomas at the abdominal
site (therefore, a 1.5% rate of hematoma evacuation for the
abdominoplasty portion) and 1 at a breast site. All patients
went on to heal and were pleased with their operative results.
When compared to reoperative hematoma rates in the plastic
surgery population in general, our use of rivaroxaban is consis-
tent with previously published data. Studying 3681 patients
having a wide array of surgical procedures, Pannucci et al re-
ported an overall reoperative hematoma rate of 2.65% when
enoxaparin was not administered and 3.38%when enoxaparin
was administered (not significant) in this study of 1567 patients
at moderate to high risk for VTE events according to the 2005
Caprini scale and 2114matched historical control patients.8
A potential limitation of our study is that we only included
patients receiving rivaroxaban during the study period. The
exclusion of patients that did not receive the medication (ie,
the 5 patients that had enoxaparin recommended by a hema-
tologist) could introduce bias by selecting out the highest risk
patients. Additionally, since this study reports on a patient
series without a comparison group, we cannot make conclu-
sions regarding superiority or inferiority of rivaroxaban use
for abdominoplasty patients with respect to VTE prevention
or complication rates. The strengths of the study include the
large number of patients and our inclusion of all consecutive
patients during our study period who took rivaroxaban with
adequate follow-up for relevant hematologic and surgical
complications. In our experience, rivaroxaban has a low rate
of adverse events such as hematoma formation and is well tol-
erated by patients without a large burden of cost. Further
study with a larger series of patients and comparison with
other VTE prophylactic regimens (medication-based or other-
wise) is warranted. While currently considered an off-label in-
dication, the 2 surgical centers continue to prescribe oral
rivaroxaban routinely to patients undergoing abdominoplasty
for VTE chemoprophylaxis.
CONCLUSIONS
Routine chemoprophylaxis with rivaroxaban (Xarelto) for
high-risk abdominoplasty patients has a low rate of VTE
events. This oral medication is well tolerated and has an ac-
ceptable complication profile.
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